ProLiFiler – Cell Line Panel Screening

The ProLiFiler service is suitable for testing of the therapeutic efficacy of test compounds on a panel of 140 human cancer cell lines using CellTiter-Glo readout.

Cell line panel screening provides efficacy data for 140 tumor cell lines from across 18 tumor types to identify the most responsive tumor entities and determine which cell lines are best suited for subsequent studies with more sophisticated 3D cell culture models or animal studies, all of which can be performed with Reaction Biology.

  • Performed on a regular basis
  • Huge cost-savings
  • Fast turnaround time: get your results in only 6 weeks
  • Option for in-depth bioinformatics analysis

Service Details

Assay Description

assay principle of the cellular proliferation assay performed with celltiter-glo

Cells were seeded in cell culture-treated 384 multi-well plates in the respective medium (A). After overnight incubation at 37 °C, compounds are dispensed by a Nanodrop Tecan D300e machine (B). Cells are treated for 72 h at 37°C at 5 % or 10% CO2 (C). Finally, cell plates are equilibrated to room temperature and the viability of cells is determined with CellTiter-Glo luminescent reagent based on the amount of ATP present (D).
 

Reproducibility

reproducibility of the cell proliferation assay was tested with bortezomib in 4 independent runs with the Z factor

The semi-automated screening process produces highly reproducible data. In every run bortezomib serves as the control reference compound. Shown here are the mean data and standard error of bortezomib results from 4 independent ProLiFiler runs.

Case Study Crizotinib - efficacy in tumor cell lines

IC50 values of Crizotinib

Identification of cell lines sensitive to the MET kinase inhibitor Crizotinib. Crizotinib was tested for anti-proliferative and cytotoxic capacity with the ProLiFiler cell line panel. Three cell lines were most receptive to treatment including MKN-45, LOVO, and Karpas 299.

Case Study Crizotinib - Tumor Origins

cell panel screening tumor entitiy ranking

Identification of the tumor origin most sensitive to the MET kinase inhibitor Crizotinib. IC50 values of Crizotinib potency on a panel of tumor cell lines were sorted based on the tumor entity. Colon tumors (red) were most susceptible to treatment.

Bioinformatic Analysis

Our bioinformatics analysis tools are available to identify the mechanism of action of your test compound and to detect suitable biomarkers for stratification of responders vs. non-responders.

MOA Finder

Biomarker Analysis

To offer these analytic tools, we have partnered with 4HF Biotec GmbH, a bioinformatics firm specializing in cancer data mining to discover new anti-cancer drugs. 4HF Biotec performs the data mining analysis based on their proprietary database and provides hands-on support with a high focus on client communication to answer your key questions.

Screening Formats

Setup: IC50 determination or single concentration testing with CellTiter-Glo readout. Drug combination testing is also an option, see an example study here.

Controls: DMSO only treatment serves as the high control. Staurosporine treatment (at 1x10-5M) serves as the low control. In every project, the IC50 value determination of a reference compound is included.

Report: A detailed report including assay conditions, methodology, and comprehensive evaluation of data as well as raw data for each analysis will be provided.

Screening schedule: Screening is performed on a regular basis. Results are available 6 weeks after study start. Please inquire about the next starting date.

Testing of subsets: For testing a subset of cell lines, or single concentration screening of multiple compounds, please see our Cell Proliferation Assay service with the free choice setup here.

Screening Facility: The ProLiFiler cell line panel screening is performed in Freiburg, Germany.

Compound requirements: In brief: 100 µl of the stock solution with 1000x the highest testing concentration or the equivalent as solid material.